Abstract 244: DHX9 inhibition is synthetically lethal with homologous recombination deficient and dMMR/MSI-H cancers and synergizes with PARP1 inhibition and chemotherapy.
Year: 2026
Type: conference-abstract
Source: Cancer Research
Institution: Arcus Biosciences (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7148654215
Cites:
Cited by:
Related to: